NYSEArca - Nasdaq Real Time Price USD

Capital Group U.S. Multi-Sector Income ETF (CGMS)

27.94 0.00 (0.00%)
As of 11:59 AM EDT. Market Open.
Loading Chart for CGMS
DELL
  • Previous Close 27.94
  • Open 27.91
  • Bid 27.91 x 2200
  • Ask 27.92 x 1000
  • Day's Range 27.90 - 27.94
  • 52 Week Range 25.00 - 28.00
  • Volume 148,970
  • Avg. Volume 498,798
  • Net Assets 1.21B
  • NAV 27.90
  • PE Ratio (TTM) --
  • Yield 5.94%
  • YTD Daily Total Return 7.65%
  • Beta (5Y Monthly) 0.00
  • Expense Ratio (net) 0.39%

The fund normally invests at least 80% of its assets in the securities of issuers domiciled within the United States. The fund invests primarily in bonds and other debt instruments, which may be represented by derivatives. In seeking to achieve a high level of current income, the fund invests in a broad range of debt securities across the credit spectrum. The fund may invest in debt securities of any maturity or duration. The fund is non-diversified.

Capital Group

Fund Family

Multisector Bond

Fund Category

1.21B

Net Assets

2022-10-25

Inception Date

Performance Overview: CGMS

View More

Trailing returns as of 9/20/2024. Category is Multisector Bond.

YTD Return

CGMS
7.65%
Category
5.37%
 

1-Year Return

CGMS
14.74%
Category
9.90%
 

3-Year Return

CGMS
0.00%
Category
0.82%
 

People Also Watch

Holdings: CGMS

View More

Sector Weightings

SectorCGMS
Technology   100.00%
Real Estate   0.00%
Utilities   0.00%
Industrials   0.00%
Energy   0.00%
Healthcare   0.00%

Related ETF News

View More

Research Reports: CGMS

View More
  • Raising target price to $61.00

    EDWARDS LIFESCIENCES CORP has an Investment Rating of SELL; a target price of $61.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • What does Argus have to say about BB?

    BLACKBERRY LTD has an Investment Rating of SELL; a target price of $2.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.

    Rating
    Price Target
     
  • Johnson & Johnson Earnings: Largely in Line as New Products Ready to Offset Stelara Biosimilars

    Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

    Rating
    Price Target
     
  • New products and M&A drive 2024 growth

    Johnson & Johnson is a diversified global healthcare company that develops, manufactures and markets products in two business segments: Innovative Medicine (formerly Pharmaceuticals) and MedTech.

    Rating
    Price Target
     

Related Tickers